Open access · CC-BY
via OpenAlex
Cell-based therapies of liver diseases: age-related challenges
K. N. Yarygin, Alexey Yu. Lupatov, Irina V. Kholodenko
Clinical Interventions in Aging · 2015 · ▲ 18 citations
Telomere attrition
Epigenetic alterations
Cellular senescence
Stem-cell exhaustion
Partial reprogramming (OSK)
Cell culture / in vitro
Human
Review
Abstract
The scope of this review is to revise recent advances of the cell-based therapies of liver diseases with an emphasis on cell donor's and patient's age. Regenerative medicine with cell-based technologies as its integral part is focused on the structural and functional restoration of tissues impaired by sickness or aging. Unlike drug-based medicine directed primarily at alleviation of symptoms, regenerative medicine offers a more holistic approach to disease and senescence(definition) management aimed to achieve restoration of homeostasis. Hepatocyte transplantation and organ engineering are very probable forthcoming options of liver disease treatment in people of different ages and vigorous research and technological innovations in this area are in progress. Accordingly, availability of sufficient amounts of functional human hepatocytes is crucial. Direct isolation of autologous hepatocytes from liver biopsy is problematic due to related discomfort and difficulties with further expansion of cells, particularly those derived from aging people. Allogeneic primary human hepatocytes meeting quality standards are also in short supply. Alternatively, autologous hepatocytes can be produced by reprogramming of differentiated cells through the stage of induced pluripotent stem cells. In addition, fibroblasts and mesenchymal stromal cells can be directly induced to undergo advanced stage hepatogenic differentiation. Reprogramming of cells derived from elderly people is accompanied by the reversal of age-associated changes at the cellular level manifesting itself by telomere(definition) elongation and the U-turn of DNA methylation. Cell reprogramming can provide high quality rejuvenated hepatocytes for cell therapy and liver tissue engineering. Further technological advancements and establishment of national and global registries of induced pluripotent stem cell lines homozygous for HLA haplotypes can allow industry-style production of livers for immunosuppression-free transplantation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.2147/cia.s97926
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
Yarygin, K.N., Lupatov, A.Y., & Kholodenko, I.V. (2015). Cell-based therapies of liver diseases: age-related challenges. <em>Clinical Interventions in Aging</em>. https://doi.org/10.2147/cia.s97926
Vancouver
Yarygin KN, Lupatov AY, Kholodenko IV. Cell-based therapies of liver diseases: age-related challenges. Clinical Interventions in Aging. 2015. doi:10.2147/cia.s97926.
BibTeX
@article{k2015Cellba,
title = {Cell-based therapies of liver diseases: age-related challenges},
author = {K. N. Yarygin and Alexey Yu. Lupatov and Irina V. Kholodenko},
journal = {Clinical Interventions in Aging},
year = {2015},
doi = {10.2147/cia.s97926},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
InTech eBooks 2018
Open access · CC-BY
Stem Cell Aging
Biogerontology 2026
Open access · OA
Mesenchymal stem/stromal cell senescence in aging and regenerative medicine: a systematic review.
Bio-Medical Materials and Engineering 2017
Citation only
Aging of bone marrow mesenchymal stromal/stem cells: Implications on autologous regenerative medicine
Neural Regeneration Research 2015
Open access · CC-BY
Mesenchymal stem cells-based therapy as a potential treatment in neurodegenerative disorders: is the escape from senescence an answer?
BioMed Research International 2017
Open access · CC-BY
Cellular Mechanisms of Liver Regeneration and Cell-Based Therapies of Liver Diseases
Stem Cells 2012
Open access · OA